ReviewJournal of orthopaedic surgery and research2026
Tumor survivors' musculoskeletal health assessment: advances in imaging biomarkers for cancer treatment-related sequelae.
Review in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With significant advancements in cancer treatment, the population of cancer survivors has grown substantially, bringing long-term health challenges to the forefront of clinical concern. Among these, cancer treatment-related musculoskeletal sequelae critically impact survivors' quality of life, functional independence, and overall survival. Musculoskeletal health deterioration-including bone density loss, sarcopenia, myosteatosis, osteonecrosis, and muscle damage-represents a complex clinical issue that requires precise evaluation and monitoring. Imaging technologies have emerged as essential non-invasive tools for identifying, quantifying, and tracking these late effects. This review systematically examines the current landscape of imaging biomarkers used to assess musculoskeletal health in cancer survivors, emphasizing their associations with common cancer therapies such as radiotherapy, chemotherapy, endocrine therapy, and targeted and immunotherapies. We explore the application and recent advances of various imaging modalities-including dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), and ultrasound imaging-in detecting and characterizing treatment-induced musculoskeletal alterations. Moreover, the review highlights the translational potential of these imaging biomarkers in clinical practice, aiming to enhance early detection, guide personalized interventions, and improve long-term outcomes for cancer survivors. By consolidating current evidence and identifying existing gaps, this article provides a comprehensive overview of the role of imaging biomarkers in addressing the critical issue of musculoskeletal health in the growing population of cancer survivors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.